Can-Fite BioPharma American Depositary Shares
CANF
15 hedge funds and large institutions have $953K invested in Can-Fite BioPharma American Depositary Shares in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
7% more funds holding
Funds holding: 14 → 15 (+1)
2.06% more ownership
Funds ownership: 2.94% → 4.99% (+2.1%)
0% more capital invested
Capital invested by funds: $950K → $953K (+$2.49K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$478K |
| 2 |
BWL
Bogart Wealth LLC
Mclean,
Virginia
|
+$11.5K |
| 3 |
Morgan Stanley
New York
|
+$2.01K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$275 |
| 5 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
+$46 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$4.14K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.22K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$763 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$189 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$6 |
CANF Hedge Fund Activity: Q3 2025 in Review
15 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q3 2025, worth a combined $953K — up 0.26% from $950K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CANF positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Sabby Management, adding an estimated $478K. The largest seller was Two Sigma Securities, cutting an estimated $4.14K.
- 15 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q3 2025, up from 14 in Q2 2025.
- Funds reported $953K of Can-Fite BioPharma American Depositary Shares stock for Q3 2025, up 0.26% quarter-over-quarter.
- 2 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q3 2025 and 1 closed out, a net change of +1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q3 2025 was Sabby Management, an estimated $478K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q3 2025 was Two Sigma Securities, an estimated $4.14K sold.
Based on aggregated 13F filings for Q3 2025.